References

  1. Decaux O, Rodon P, Ruelland A, Estepa L, Leblay R, Grosbois B. Épidémiologie descriptive des gammapathies monoclonales. Expérience d’un centre hospitalier général et d’un service de médecine interne de centre hospitalier et universitaire. Rev Med Interne. 2007; 28(10): 670- 6. Google Scholar

  2. Rajkumar SV, Dimopoulos MA and al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov; 15(12): e538-48. PubMed | Google Scholar

  3. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003 Jun; 121(5): 749-57. PubMed | Google Scholar

  4. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep; 36(3): 842-54. PubMed | Google Scholar

  5. Greipp Pr, San Miguel J, Durie Bg et Al. International Staging System for multiple myeloma. J Clin Oncol. 2005 May 20; 23(15): 3412-20. PubMed | Google Scholar

  6. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M et al. International uniform response criteria for multiple myeloma. Leukemia. 2006 Sep; 20(9): 1467-73. PubMed | Google Scholar

  7. Nnonyelum ON, Anazoeze MJ, Eunice NO, Emmanuel OO, Stella AT, Marcus AI et al. Multiple myeloma in Nigeria: a multi-centre epidemiological and biomedical study. Pan Afr Med J. 2015 Nov 24; 22: 292. PubMed | Google Scholar

  8. El Husseiny NM, Kasem N, El Azeeim HA, Mattar MW. Multiple myeloma: a descriptive study of 217 Egyptian patients. Ann Hematol. 2014 Jan; 93(1): 141-5. PubMed | Google Scholar

  9. Ndiaye FSD, Pouye A, Fall S, Diallo S, Ndongo S, El Kacimi S et al. Présentation clinique du myélome multiple à Dakar (Sénégal): à propos de 71 observations. J Afr Cancer. 2011; 3(1): 8-11. Google Scholar

  10. Tolo DA, Sawadogo D, Nanho DC, Kouakou B, Méité N’D, Ayémou R et al. Characteristics and Results of the Treatment of Multiple Myeloma in the Subject under the Age of 65 at the University Hospital of Yopougon in Abidjan, Côte d’Ivoire. Adv Hematol. 2013; 2013: 583051. PubMed | Google Scholar

  11. Kakpovi K, Oniankitan O, Houzou P, Koffi-Tessio VES, Tagbor KC, Fianyo E et al. Profil du Myélome Multiple des os en consultation rhumatologique à Lomé (Togo). Rev Mar Rhum. 2014; 27: 48-53. Google Scholar

  12. Younes M, Hachfi H, Hammouda F, Younes K, Ben Hammouda S, guirim MJ et al. Les facteurs pronostiques de survie au cours du myélome multiple. Tunis Med. 2014 Jun; 92(6): 399-405. PubMed | Google Scholar

  13. Ngolet LO, Kocko I, Atipo Tsiba Galiba FO, Ockouango J, Elira Dokekias A. Parcours préhospitalier du patient ayant un myélome multiple à Brazzaville. Health Sci Dis. 2016; 17(3): 88-91. Google Scholar

  14. Ngolet LO, Kocko I, Galiba Atipo FO, Guelongo Okouango Ova JD, Ntsiba H, Elira Dokekias A. Le myélome multiple symptomatique à Brazzaville: à propos de 40 cas. Ann Univ M Ngouabi. 2016; 16(1): 1-7. Google Scholar

  15. Gavriatopoulou M, Terpos E, Kastritis E, Dimopoulos MA. Current treatments for renal failure due to multiple myeloma. Expert Opin Pharmacother. 2016 Nov; 17(16): 2165-2177. PubMed | Google Scholar

  16. Bergsagel PL. Where We Were, Where We Are, Where We Are Going: progress in Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2014; 199-203. PubMed | Google Scholar

  17. Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K et al. Clinical profiles of multiple myeloma in Asia -An Asian Myeloma Network study. Am J Hematol. 2014; 89(7): 751-6. PubMed | Google Scholar